Quintrio
Home

LABORATORY ANALYTICAL INSTRUMENTS

Rapid Micro Biosystems, Inc. Class A Common Stock

RPID

Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.

Last trade $0.7354
Day change -$0.0046 (-0.62%)
Day range $0.723 – $0.757
Volume 4,273,830
Market cap $37M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$37.12M
Price / earnings
—
Price / book
2.09×
Price / sales
1.06×
EV / sales
1.18×
EV / EBITDA
-0.89×

Profitability

Earnings per share
-$1.02
Return on assets
-87.6%
Return on equity
-288.48%
Dividend yield
0%

Liquidity and leverage

Debt / equity
1.08×
Current ratio
2.55×
Quick ratio
1.51×
Cash ratio
0.81×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$40.39M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for RPID, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$8.05M$8M$11.28M$7.84M$7.26M$7.21M$8.22M$7.6M
Cost of revenue$6.84M$7.63M$11.61M$7.14M$6.99M$6.8M$7.24M$6.98M
Gross profit$1.21M$371K-$328K$696K$275K$404K$981K$622K
Selling, general and administrative$10.2M$10.86M$8.66M$8.54M$9.19M$8.44M$7.81M$9.05M
Research and development$3.33M$3.36M$3.22M$3.53M$3.23M$3.62M$3.4M$3.61M
Total operating expenses$13.53M$14.22M$11.88M$12.07M$12.42M$12.07M$11.21M$12.66M
Operating income-$12.32M-$13.85M-$12.21M-$11.37M-$12.15M-$11.66M-$10.23M-$12.04M
Interest expense-$646K-$639K-$673K-$393K-$12K-$12K-$12K-$11K
Income before taxes-$12.88M-$14.27M-$12.48M-$11.5M-$11.85M-$11.26M-$9.68M-$11.31M
Income taxes$45K$8K$14K$8K$11K$7K-$9K$13K
Net income-$12.92M-$14.28M-$12.5M-$11.51M-$11.86M-$11.26M-$9.67M-$11.32M
Net income attributable to common shareholders-$12.92M-$14.28M-$12.5M-$11.51M-$11.86M-$11.26M-$9.67M-$11.32M
EBITDA-$11.65M-$13.15M-$11.42M-$10.57M-$11.34M-$10.81M-$9.36M-$11.18M
Basic earnings per share-$0.27-$0.31-$0.28-$0.26-$0.27-$0.26-$0.22-$0.26
Diluted earnings per share-$0.27-$0.31-$0.28-$0.26-$0.27-$0.26-$0.22-$0.26

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Beats Revenue Estimates

Rapid Micro Biosystems reported a Q3 loss of $0.22 per share, missing EPS expectations by 10% despite beating revenue estimates at $9.53 million. The company has underperformed the market significantly, down 77.6% year-to-date. With a Zacks Rank #3 (Hold) rating and mixed estimate revisions, the stock is expected to perform in line with the market.

Zacks Investment Research

DarioHealth Corp. (DRIO) Reports Q3 Loss, Tops Revenue Estimates

DarioHealth Corp. (DRIO) reported a quarterly loss of $0.44 per share, beating consensus estimates of $0.51 loss, with a 13.73% earnings surprise. Revenues reached $5.31 million, slightly exceeding expectations. However, the stock has plummeted 81.3% year-to-date compared to the S&P 500's 11.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

Pulse Biosciences, Inc (PLSE) Reports Q3 Loss, Misses Revenue Estimates

Pulse Biosciences reported a Q3 loss of $0.32 per share, beating EPS estimates but missing revenue expectations with $0.4 million versus consensus estimates. The company has significantly outperformed the S&P 500 this year with a 315.6% gain. The stock holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

Tactile Systems Technology (TCMD) Q3 Earnings Surpass Estimates

Tactile Systems Technology (TCMD) beat EPS estimates with $0.31 per share versus consensus of $0.30, but missed revenue expectations at $91.86 million. The stock has underperformed the market by 20.6% year-to-date. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical-Instruments industry ranks in the top 42% of Zacks industries.

GlobeNewswire Inc.

Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering

Rapid Micro Biosystems (RPID) announced a pricing of an underwritten offering of 3.58 million shares of Class A common stock at $1.955 per share, combined with Series A and Series B warrants. Bain Capital Life Sciences and Armistice Capital are investing approximately $9.8 million, with potential additional proceeds of $21.7 million if all warrants are exercised. The offering is expected to close on May 20, 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 29, 20101-for-30reverse split